FAM122A ensures cell cycle interphase progression and checkpoint control as a SLiM-dependent substrate-competitive inhibitor to the B55⍺/PP2A phosphatase
Preprint in bioRxiv (March 2023)
The most recent citing publications are shown below. View all 17 publications that cite this research output on Dimensions.
Inhibition of tamoxifen's therapeutic effects by emodin in estrogen receptor-positive breast cancer cell lines
Article in Annals of Surgical Treatment and Research (November 2019)
Cyclin D1 overexpression associated with activation of STAT3 in oral carcinoma patients from South India.
Article in Journal of Cancer Research and Therapeutics (January 2018)